Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV
TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has received approval from the Ministry of Health and Prevention of the United Arab Emirates ("UAE") ("Clinical Trial Approval") to conduct a Phase II/III...
HIGH-TECH DROIDS UNITE AT DORSETT WANCHAI
To Ensure Guests a Safe & Healthy Quarantine Stay From HKD990nett per night with Daily 3 Meals & USD24-110 Cash Credits HONG KONG, April 13, 2022 /PRNewswire/ -- The award-winning Dorsett Wanchai, Hong Kong continues to uphold the #DorsettCares promise by recruiting a new army of high-tech droids and solutions at the hotel to bring its comprehensive hygiene measures...
AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
SHANGHAI, April 13, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery. In 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix (NASDAQ:...
MILVIK MAKES HEALTHCARE AFFORDABLE WITH NEW HEALTH APP AND HEALTH WALLET
DHAKA, Bangladesh, April 13, 2022 /PRNewswire/ -- Milvik, the leading digital healthcare solutions provider in Bangladesh, has launched the Milvik Health+ App to enhance accessibility to high-quality healthcare while allowing customers to enjoy more benefits from their Milvik health subscriptions through the Health Wallet feature. MILVIK LAUNCHES HEALTH+ APP WHICH INCLUDES...
CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimization of CS2006/NM21-1480 allowed optimal PD-L1 blockade and 4-1BB stimulation concomitantly, at a broad dose range thereby and facilitating dose-finding in the clinic CS2006/NM21-1480 was efficacious as monotherapy in both hot and cold tumor models; combination with a CD3-T cell engager resulted in enhanced anti-tumor activity, with increased CD8-positive...
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea, April 13, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) and Daewoong Pharmaceutical (KRX: 069620.KS) today announced expansion of their open collaboration strategy...
JUNIPER BIOLOGICS ACQUIRES CELL-MEDIATED GENE THERAPY TG-C LD FOR TREATMENT OF KNEE OSTEOARTHRITIS
$600 million USD acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa SINGAPORE, April 13, 2022 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing and commercializing novel therapies announced today that it has gained the licensing rights to develop and commercialize TG-C...
Cambrex Completes Large-Scale US API Expansion
EAST RUTHERFORD, N.J., April 13, 2022 /PRNewswire/ -- Cambrex announced today the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to...
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 study in 2023 SEONGNAM, South Korea, April 13,...
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its Phase I first-in-human study. YL201 uses a novel "TMALIN" (Tumor Microenviroment Activable Linker) ADC...
